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Abstract: The present study highlights the biological effects of chromomycin A2 toward 
metastatic melanoma cells in culture. Besides chromomycin A2, chromomycin A3 and 
demethylchromomycin A2 were also identified from the extract derived from Streptomyces 
sp., recovered from Paracuru Beach, located in the northeast region of Brazil. The 
cytotoxic activity of chromomycin A2 was evaluated across a panel of human tumor cell 
lines, which found IC50 values in the nM-range for exposures of 48 and 72 h. MALME-3M, 
a metastatic melanoma cell line, showed the highest sensitivity to chromomycin A2 after 
48h incubation, and was chosen as a model to investigate this potent cytotoxic effect. 
Treatment with chromomycin A2 at 30 nM reduced cell proliferation, but had no 
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significant effect upon cell viability. Additionally, chromomycin A2 induced accumulation 
of cells in G0/G1 phase of the cell cycle, with consequent reduction of S and G2/M and 
unbalanced expression of cyclins. Chromomycin A2 treated cells depicted several cellular 
fragments resembling autophagosomes and increased expression of proteins LC3-A and 
LC3-B. Moreover, exposure to chromomycin A2 also induced the appearance of acidic 
vacuolar organelles in treated cells. These features combined are suggestive of the 
induction of autophagy promoted by chromomycin A2, a feature not previously described 
for chromomycins. 
Keywords: Streptomyces; autophagy; cytotoxicity; chromomycin; marine  
microorganisms; Brazil 
 
1. Introduction 
Chromomycins are glycosylated tricyclic polyketides members of the aureolic acid group of 
antitumor antibiotics. These golden-yellow compounds are produced by actinomycetes, mainly those 
from the Streptomyces genus. Although chromomycins were initially isolated due to their antibacterial 
activity, the main pharmacological interest in such molecules regards their anticancer activity [1]. 
Mithramycin was the first compound described from this class, in the early 1950s, and its 
production has been associated with Streptomyces argillaceus, S. plicatus, S. tanashiensis and S. 
atroolivaceus [1,2]. Clinically, it has been used to treat certain types of cancer, such as testicular 
carcinoma, and Paget’s disease [3–5]. In addition, lately, this compound has been finding new 
therapeutic uses in the treatment of cancer and other diseases [6]. 
Chromomycin A3, the best-known compound among the chromomycins, was isolated in 1958 from 
the fermentation broth of S. griseus [7,8]. It is a very potent inhibitor of tumor cell growth and also 
shares some bioactivities with mithramycin, such as inhibition of neuronal apoptosis [9] and induction 
of erythroid differentiation in K562 cells [10]. However, the clinical use of these compounds has been 
limited due to toxicity towards liver, kidneys and gastrointestinal organs [11]. 
Several studies have shown that the antitumor effect of chromomycins and other aureolic acids is 
partly owned to non-intercalating interaction with G-C regions in the minor grove of the DNA double 
helix, by forming dimeric complexes with the Mg2+. This interaction affects the processes of 
replication and, mainly, transcription of DNA, and is determinant for the cytotoxic activity [12,13]. 
The chromomycin studied herein was isolated from a strain of Streptomyces sp. recovered from 
sediment collected at Paracuru Beach, located on the west coast of Ceará State, on the northeastern 
region of Brazil. This study is part of a larger project, which is comprised of the biotechnological 
prospection of marine bacteria associated to sediments from the tropical coast of Brazil by means of 
dereplication of cytotoxic extracts and isolation of bioactive compounds. A further mode of action 
evaluation also constitutes a goal of the project. Therefore, the present article, one of the first 
originated within this venture, reports on evidences that show the induction of autophagy in melanoma 
cells by chromomycin A2, a feature not yet described for this class of compounds. 
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2. Results and Discussion 
Actinomycetes are Gram-positive bacteria widely distributed in soil from terrestrial and aquatic 
environments. These microorganisms play an essential role in decomposition of complex mixtures and 
recycling of nutrients. Moreover, they are renowned factories of bioactive secondary metabolites, 
including those of clinical significance, and account for the biosynthesis of nearly 40% known 
microbial natural products [14,15]. Within these producers of bioactive compounds, members of their 
largest genus, Streptomyces, deserve special consideration since they are responsible for making 
around 75% of all actinomycete-derived bioactive compounds [16], and 60% of clinically valuable 
antibiotics [17]. The Streptomyces sp. strain studied herein (Figure 1a) was selected based on a cell 
based screening using MTT assay, in which its EtOAc extract presented cytotoxicity towards the 
adenocarcinoma HCT-116 cell line in the sub-microgram range, and was identified based on the 16S 
sequencing and Basic Local Alignment Search Tool (BLAST) analysis. 
2.1. Isolation and Cytotoxicity of Chromomycin A2 
The active EtOAc extract of Streptomyces sp. was fractionated using reversed phase flash 
chromatography, resulting in 15 fractions (F1–F15). LC-HRESIMS analysis of fraction F8 revealed 
the presence of peaks with pseudomolecular ions at m/z ([M + H]+) of 1211.5476, (calcd. for 
C59H87O26, 1211.5480), 1183.5164 (calcd. for C57H83O26, 1183.5167) and 1197.5310 (calcd. for 
C58H85O26, 1197.5324), corresponding to the known compounds chromomycin A2 (1), chromomycin 
A3 (2) and demethylchromomycin A2 (3) (Figure 1b), respectively. Fraction F8 was chromatographed 
on a reversed phase column using a gradient H2O/CH3CN and the subfractions were finally purified by 
repeated semipreparative and preparative HPLC to yield 1.0 mg of the major compound 1 as a yellow 
solid and negligible amounts of compounds 2 and 3. Compound 1 was identified as chromomycin A2, 
by means of HRMS and 1H NMR spectroscopic data (Supplementary Figures S1 and S2) and 
comparison with previously published data [18–20]. 
Figure 1. Bacterial strain and chemical structure. (a) Photograph of Streptomyces sp. 
plated on solid A1 media; (b) Structures of chromomycin A2 (1) [21,22], chromomycin A3 
(2) [7,8] and demethylchromomycin A2 (3) [23,24]. 
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Chromomycin A2 (1), also known as aburamycin A, was firstly isolated in 1957 [21,22] from  
S. aburaviensis and, since then, it has been reported to be produced by other Streptomyces species [25–27]. 
Chromomycin A2, differently from chromomycin A3, has not been extensively studied concerning its 
biological activity. It has been shown, however, that chromomycin A2 may be up to 10 times more 
cytotoxic than chromomycin A3 [11,28] and both compounds are active within the low nM-range. 
Demethylchromomycin A2 was also isolated from S. aburaviensis in 1988, and presented inhibitory 
activity against gram-positive bacteria and towards the P-388 leukemia model in mice, but it was less 
active then chromomycin A3 in the experimental cancer model [23,24]. 
On the 7-cell line panel of the present study, chromomycin A2 also induced cytotoxicity in the  
nM-range after 48 or 72 h incubation (Table 1). Interestingly, exposure of cells to chromomycin A2 
during a shorter period, for example, 24 h, was insufficient to induce a notable effect on cell 
proliferation, even at concentrations 20 to 60 times higher than the IC50 calculated for cells exposed 
during longer periods (72 h). Chromomycin A2 was slightly selective towards cancer cells when 
compared to non-tumor cell line MRC-5. The obtained selective index after 72 h incubation (IC50 
normal cells/IC50 tumor cells) ranged from 2.2 in metastatic prostate PC-3M cells to 17 in adenocarcinoma 
HCT-116 cells. Lu et al. [28] evaluated the cytotoxicity of chromomycin A2 against the human 
umbilical vein endothelial cells (HUVEC) and obtained IC50 values of 8 nM, much lower than the one 
obtained in the present study for the fetal lung fibroblast MRC-5, although for the adenocarcinoma cells 
HCT-116, the IC50 value was 5 nM, comparable to the one obtained herein (6.3 nM, Table 1). Thus, it can 
be suggested that cytotoxicity is variable towards non-tumor cells of different origins, such as observed 
with tumor cells. Doxorubicin was used as positive control and showed IC50 values ranging from 6 
nM, for HL-60 leukemia cells, to 3280 nM, for fetal lung fibroblast MRC-5, after 72 h incubation 
(Supplementary Table S1). 
Table 1. Cytotoxicity of chromomycin-A2 (1) on select cell lines. Activity of 1 was 
evaluated using the MTT assay after 24, 48 and 72 h incubation. The IC50 [nM] values and 
95% CI were obtained via nonlinear regression. n.d.—not determined. 
Cell Line Histological Origin (Duplication Time) 
IC50 [nM] (CI 95%) 
24 h 48 h 72 h 
HCT-116 Colon adenocarcinoma (17.4 h) >400 
21.6  
(12.1–38.5) 
6.3 
(4.6–8.7) 
HL-60 Promyelocitic leukemia (28.6 h) >200 
22.3 
(19.7–25.3) 
10.1 
(8.13–12.46) 
MALME-3M Metastatic melanoma (46.2 h) >400 
16.7 
(7.2–38.5) 
18.7 
(14.6–24.3) 
OVCAR-8 Ovarian adenocarcinoma (26.1 h) >200 
33.8 
(28.2–40.5) 
8.8 
(7.7–9.9) 
PC-3M Metastatic prostate carcinoma (20 h) >400 
209.8 
(122.5–359.5) 
49.0 
(27.5–87.3) 
SF-295 Glioblastoma (29.5 h) >200 n.d. 
20.8 
(18.8–23.0) 
MRC-5 Lung fibroblast (27 h) > 400 
131.7 
(86.6–200.3) 
109.0 
(82.0–144.8) 
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The malignant melanoma cell MALME-3M was among the most sensitive cell lines to 
chromomycin A2, and thus was chosen to further evaluate the mechanisms underlying chromomycin 
A2 cytotoxic effects. Malignant melanoma, classified by genetic defects within pigment-producing 
melanocytes, is attributed to the largest number of skin related cancer deaths [29]. While protective 
measures can be taken, the aggressive and rapid metastatic properties of melanoma-based tumors 
continues to challenge clinical practices [29]. This, combined with unique epidemiological concerns [30] 
and lack of viable treatment options [31], places melanoma among the most fatal cancers. Although the 
cytotoxicity of chromomycin A2 was comparable to doxorubicin for most cancer cells, MALME-3M 
was around 13 times more sensitive to chromomycin A2 than to the positive control, whereas, in  
PC-3M, doxorubicin was almost 50 times more active than chromomycin A2. Additionally, herein, 
chromomycin A3 (isolation and identification procedures described in supplementary material) was 
also assayed against MALME-3M under the same conditions (48 h incubation) and presented an IC50 
value of 762 nM, which represents a 45 times decrease in cytotoxicity when compared to 
chromomycin A2. It was not possible to obtain enough material of demethylchromomycin A2 to run 
the biological assays. 
The potent cytotoxic activity of chromomycins, mithramycin and other structurally similar members 
of the aureolic acids arises from H-bonds created between the aglycon moiety and guanine bases from 
the minor grove of the DNA double-helix [2]. The sugar subunits, on the other hand, partake in this 
interaction by stabilizing the complex compound-DNA and influencing the sequence specificity with 
which the molecule will bind to DNA [32,33]. Mithramycin and chIromomycins share the same 
aglycon, however, the slight differences among their glycosidic structures affect the plasticity of their 
interaction with DNA. The added methyl and acetyl groups on chromomycin A3 (2) makes binding 
more stable and specific when compared to that of mithramycin [34]. 
To the best of our knowledge, chromomycin A2 has not been directly experimented in a  
DNA-binding biological model, such as chromomycin A3 and mithramycin [35,36]. It is, however, 
expected that DNA-binding patterns of both chromomycins be comparable. Nevertheless, differently 
from both chromomycin A3 and mithramycin, chromomycin A2 carries an extra acetyl group on one 
of the sugar units, rendering that interaction with DNA, by analogy at least, more stable than that with 2. 
Thus, we decided to further evaluate the mechanisms underlying chromomycin A2 effects on 
MALME-3M using two concentrations, 10 and 30 nM, that comprised the obtained IC50 value  
(16.7 nM), and an incubation time of 48 h compatible to the doubling time for this cell line (46.2 h).  
As positive controls, we used doxorubicin (100 nM), a natural anthracycline currently used in  
cancer chemotherapy [37], and rapamycin (30 nM), a natural macrolide currently used as an 
immunosuppressant drug and a typical autophagy reference compound for in vitro studies [38]. 
Chromomycin A3 was also included in the analysis to compare its activity profile with that found for 
chromomycin A2. 
2.2. Chromomycin A2 Alters Cell Cycle of Metastatic Melanoma Cells MALME-3M 
Initial flow cytometry analysis showed that chromomycin A2 had no influence on cell viability, but 
significantly reduced cell density at 30 nM, much like the positive controls (Figure 2a and 
Supplementary Figure S5). Subsequent analysis of the cell cycle revealed exposure of MALME-3M to 
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chromomycin A2 at 30 nM significantly increased accumulation of cells in the G0/G1 phase (Figure 2b 
and Supplementary Figure S6). Western blot analysis strengthened this observation by revealing 
increased expression of cyclins D1 and D3, which are usually highest during G1, and reduced 
expression of cyclins A2 and B1, which are relevant throughout S and G2 phases, after treatment with 
chromomycin A2 at 30 nM (Figure 2c). Chromomycin A3, at the tested concentration 30nM, presented 
no significant effect on the parameters evaluated. 
Figure 2. Effect of chromomycin-A2 (C-A2) on cell viability and cell cycle progression of 
MALME-3M cells treated with controls, chromomycin A2 at 10 and 30 nM or 
chromomycin A3 at 30 nM for 48 h. (a) Flow cytometry analysis of cell density and cell 
viability with propidium iodide staining; (b) Doughnut graphs depicting distribution of cell 
cycle phases (A, DMSO; B, doxorubicin; C, rapamycin; D, chromomycin A2 10 nM; E, 
chromomycin A2 30 nM; F, chromomycin A3, C-A3, 30 nM); (c) Expression of key cell 
cycle regulating proteins by western blotting. DMSO (0.4% v/v) was used as negative 
control (−) and doxorubicin (100 nM) and rapamycin (30 nM) were used as positive 
controls. * p < 0.05. Data on graphs correspond to the mean ± standard error of the mean 
from at least three independent experiments. 
 
2.3. Alterations in Morphology and Expression of Autophagic Proteins by Chromomycin A2 
Conventional May-Grumwald-Giemsa staining revealed interesting morphological characteristics, 
as numerous cellular rounded cytoplasm-containing vesicles surrounding the nucleus, resembling 
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autophagosomes, appeared in MALME-3M cells treated with chromomycin A2 at 30 nM during 48 h 
(Figure 3a). In addition, a strong reduction of cell density was noticeable. Flow cytometry analysis 
showed a significant increase of internucleosomal fragmentation in cells exposed to chromomycin A2 
at 30 nM (Figure 3b). Analysis of relevant protein markers for autophagy and apoptosis by western 
blot supported the involvement, mostly, of the autophagic process following treatment of MALME-3M 
with chromomycin A2. The increased expression of beclin-1 was evident, when compared to control 
cells (Figure 3c). This protein has a central role in the regulation of autophagy in mammals, especially 
during autophagosome formation [39]. LC3 proteins also assist initial autophagosome formation 
through its conversion to a membrane-bound lipidated form by a pro-autophagic signal, which remains 
bound to the luminal membrane until fusion with lysosomes is completed [40]. Lipidation of LC3 
family members, LC3-A and LC3-B, is an autophagosomal marker [41] and, in the present study, 
expression of both was clearly increased after treatment with chromomycin A2 at 10 and 30 nM 
(Figure 3c). Caspase 3 and PARP play crucial role in the execution-phase of apoptosis. The cleaved 
forms of Caspase 3 and PARP trigger their active state [42,43]. The treatment with chromomycin A2 
had no obvious effect in the expression of the later proteins (Figure 3c). Although Caspase 3 and 
PARP were not altered by chromomycin A2, it is important to mention that generally autophagy is 
followed by apoptosis in cells exposed to anticancer agents [44]. In fact, many signal transduction 
pathways may regulate both processes, explaining the sequential nature of the cellular events [44]. As 
observed for cell viability, cell density and cell cycle progression, chromomycin A3 at 30 nM did not 
induce any evident alterations in treated cells. 
2.4. Induction of Autophagy by Chromomycin A2 
Autophagy is an intracellular catabolic pathway that involves the clearance or recycling of 
unessential or dysfunctional proteins and organelles. This process may promote cell survival by 
serving as an alternate energy source during starvation periods, thus maintaining homeostasis and cell 
viability [45]. 
The formation of autophagosomes is a key step for the cellular installation of the autophagic 
process. These are rounded vesicles with double-layer membranes that sequester a portion of 
cytoplasm (with protein and organelles to recycle) to be later delivered to lysosomes, for digestion by 
acid hydrolases [45]. Thus, for recognition of this acidic compartment, acridine orange was used due to 
its propriety of moving across biological membranes when uncharged. Its protonated form, on the 
other hand, accumulates in the acidic vacuolar organelles (AVOs) and fluoresces in an orange tone [46]. 
Staining of MALME-3M cells treated with chromomycin A2 at 30 nM revealed the appearance of 
numerous AVOs, comparable to doxorubicin, shown by concentration of the dye in the vesicles 
(Figure 4). Rapamycin, recognized as a classical autophagy inductor, did not induce a significant 
accumulation of AVOs. It is important to mention that autophagy is an orchestrated cascade of events 
with a time course that can be variable dependent on the stimulus. 
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Figure 3. Chromomycin-A2 (C-A2) induces alterations in morphology and expression of 
regulatory proteins of autophagy in MALME-3M cells. (a) Photomicrographs of  
May-Grumwald-Giemsa-stained MALME-3M cells exposed to chromomycin A2 at 30 nM 
for 48 h in comparison to negative control cells. Arrows indicate the autophagosomes 
resembling fragments (solid line arrow) and internucleosomal fragmentation (dotted  
line arrow). (b) Flow cytometry analysis of nuclear DNA fragmentation with propidium 
iodide staining; (c) Expression of key apoptosis and autophagy regulating proteins  
by western blotting. DMSO (0.4% v/v) was used as negative control (−) and doxorubicin 
(100 nM) and rapamycin (30 nM) were used as positive (+) controls. * p > 0.05. Data  
on graph correspond to the mean ± standard error of the mean from at least three 
independent experiments. 
 
Although chromomycin A2 has not been studied to the extent of chromomycin A3, no evidences 
depicting the induction of autophagy by any of the aureolic acids have been reported. However, it is 
not unlikely that starvation conditions, generated by the deprivation of nutrients as a consequence of 
reduced transcription activity, may be connected to the observations emphasized herein. The 
association between these two processes should be further addressed in order to establish causality of 
the relationship; however, the induction of autophagy might influence the way by which the biological 
activities of aureolic acids are engaged in a clinical panorama from now on. 
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Figure 4. Chromomycin-A2 (C-A2) induces autophagy on MALME-3M cells. (a) 
Confocal images depicting the formation of acid vesicular organelles (AVOs) with  
double-staining with acridine orange (AO) on MALME-3M cells treated for 48h (A, 
DMSO; B, doxorubicin; C, rapamycin; D, chromomycin A2 10 nM; and E, chromomycin 
A2 30 nM; F, chromomycin A3, C-A3, 30 nM), horizontal bars = 10 μm; Representative 
histograms (b) and graph (c) of flow cytometry quantification of AVOs with AO staining. 
DMSO (0.4% v/v) was used as negative control (−) and doxorubicin (100 nM) and 
rapamycin (30 nM) were used as positive controls. * p > 0.05. Data on graph correspond to 
the mean ± standard error of the mean from at least three independent experiments. 
 
3. Experimental Section 
3.1. General Experimental Procedures 
NMR spectra were obtained in a a Bruker Avance III spectrometer (500 and 125 MHz for 1H and 
13C NMR, respectively) equipped with a 1.7 mm TCI MicroCryoProbe™ (Bruker Biospin, Fällanden, 
Switzerland). Chemical shifts were reported in ppm using residual CDCl3 (δ 7.27) as internal 
reference. LC-MS analysis was performed on an Agilent 1100 single Quadrupole (Agilent 
Tehcnologies, Santa Clara, CA, USA), while the dereplication was carried using in house and 
commercial databases (Chapman & Hall Dictionary of Natural Products). HRESIMS spectra were 
acquired using a Bruker maXis QTOF (Bruker Daltonik GmbH, Bremen, Germany) mass spectrometer 
coupled to an Agilent 1200 LC (Agilent Technologies, Waldbronn, Germany) UV spectra were 
obtained with an Agilent 1200 DAD. Preparative and semipreparative HPLC was performed using a 
Gilson GX-281 system (Gilson Inc., Middleton, WI, USA). 
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3.2. Isolation and Identification of Bacterial Strain 
Bacterial strain (previously identified as BRA-090) was recovered from a marine sediment sample 
collected at Paracuru Beach [03°23'S; 39°54'W], located on the west coast of Ceará State, on the 
northeastern region of Brazil. Freshly collected sediment was left to air dry under a flow hood during 
48h. Using a sterile sponge plug, dry sediment was serially stamped onto Petri dishes containing trace 
mineral agar (0.1% glucose, 0.1% yeast extract, K2HPO4, Na2HPO4, KNO3, NaCl, MgSO4·7H2O, 
CaCl2·2H2O and 18% agar in 75% seawater, and added a solution containing FeSO4·7H2O, 
ZnSO4·7H2O, MnSO4·4H2O, CuSO4·5H2O, CoSO4·7H2O, H3BO3 and (NH4)6Mo7O24·4H2O), 
supplemented with 0.1 mg/mL cycloheximide (Sigma Aldrich, Saint Louis, MI, USA), and incubated 
at 28 °C. After nearly 4 weeks, an individualized colony of the strain was transferred to a new dish 
layered with A1 agar (10% soluble starch, 4% yeast extract, 2% peptone and 18% agar in 75% filtered 
sea water) for purification. 
For taxonomic identification of the strain, a molecular based approach was carried out. Microbial 
genomic DNA was extracted from a pure culture of the bacteria using a method adapted from that of [47]. 
An aliquot from fresh bacterial culture grown during 4 days was centrifuged (215 g; 3 min) to remove 
excess culture medium, then added to 1 mL of lysis buffer [2% (m/v) CTAB, 1.4 M NaCl, 20 mM 
EDTA, 100 mM Tris-HCl (pH 8.0)], freshly added with 5 µg proteinase K (v/v; Invitrogen) and 0.5%  
2-mercaptoethanol. Sample was frozen at −80 °C for 3–5 min and soon after thawed in a dry bath for 3 
min at 65 °C; this procedure was repeated two times. Next, an equal volume of the solution was added 
to phenol:chloroform:isoamyl alcohol (25:24:1; v/v), homogenized and centrifuged (7 min; 9520 g; 
4 °C). The aqueous phase was recovered and mixed with 400 µL of chloroform, then centrifuged  
(5 min; 9520 g; 4 °C). Genomic DNA was precipitated by addition of 0.75× volume of ammonium 
acetate and 1 volume of ice-cold isopropyl alcohol, followed by centrifugation (30 min, 9520× g, 4 °C). 
The supernatant was discarded; the pellet was washed with ice-cold ethanol (70%), centrifuged 
(10 min; 13,709× g; 4 °C) and dissolved in 35–50 µL of TE buffer (10 mM Tris-HCL e 1 mM de 
EDTA) overnight. Genomic DNA was quantified using a microvolume spectrophotometer (Thermo 
Scientific; NanoDrop 2000c, Wilmington, NC, USA). 
Amplification of the 16S rRNA gene was done in a total volume of 25 µL containing PCR  
mix (AmpliTaq Gold® 360 Master Mix, Foster City, CA, USA), 0.1 nM of each primer, 27F  
(5′-AGAGTTTGATCCTGGCTCAG-3′) and 1492R (5′-TACGGCTACCTTGTTACGACTT-3′), and  
100–150 ng of DNA. PCR was initiated with a denaturation step at 94 °C for 12:30 min followed by  
35 cycles of the following protocol: denaturation at 94 °C for 1 min, extension at 72 °C for 1 min and 
annealing at 63 °C for 1 min. For the last cycle, 7 min of extension at 72 °C was performed. PCR 
products were visualized by electrophorese on 1% agarose gels stained with SYBR safe and Blue 
Juice. PCR products were purified by mixing 5 µL of PCR reaction product with 2 µL of ExoSAP-IT 
(Affymetrix Inc., Cleveland, OH, USA), then incubating samples at 37 °C for 15 min, followed by a 
second incubation at 80 °C for 15 min. DNA sequencing was performed on an Applied Biosystems 
3500 Genetic Analyzer using the ABI PRISM BigDyeTM Terminator Cycle Sequencing kit (Applied 
Biosystems, Foster City, CA, State, USA) and the same primers used for amplification, following the 
protocols supplied by the manufacturer. 
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The obtained forward and reverse sequences were aligned and the contig generated with assistance 
of the software Geneious 7 (Biomatters Ltd., Auckland, New Zealand) and compared to sequences 
within the NCBI database (http://www.ncbi.nlm.nih.gov/) using the BLAST. 
3.3. Up-Scale Bacterial Growth and Isolation of Chromomycin A2 
Streptomyces sp. was grown in A1 broth (10% soluble starch, 4% yeast extract and 2% peptone) 
supplemented with 0.1% calcium carbonate, and solutions of Fe2(SO4)3 and KBr, in 75% filtered sea 
water. The culture broth (14 L) was fermented during 7 days under 150 rpm agitation at 28 °C, and 
extracted with EtOAc (1:1). The solvent was removed under reduced pressure to yield 570 mg of crude 
extract. The dried extract was subjected to reversed phase flash chromatography (RediSep C18, 
gradient H2O:MeOH from 20% to 100% MeOH in 12.5 min + 100% MeOH for 15 min, flow rate 
10 mL/min, UV detection at 210 and 279 nm) to obtain 15 fractions (F1–F15) of approximately 18 mL 
each. Subfraction F8 was analyzed by LC-HRESIMS employing a Zorbax SB-C8 column 
(2.1 × 30 mm) and a gradient elution profile of 10% B (90% CH3CN, 10% H2O, 1.3 mM TFA, 1.3 mM 
ammonium formiate)/90% A (10% CH3CN, 90% H2O, 1.3 mM TFA, 1.3 mM ammonium formiate) to 
100% B in 6 min, kept at 100% B for 2 min and returned to 10% B for 2 min at flow of 300 µL/min. 
Peaks with m/z 1211.5476, 1183.5164 and 1197.5310 were identified as chromomycin A2 (1), 
chromomycin A3 (2) and demethylchromomycin A2 (3), respectively. Subfraction F8 was subjected to 
preparative HPLC (Zorbax C8, 2.1 × 250 mm, gradient H2O:CH3CN from 30% to 70% CH3CN in 
35 min, flow rate 20 mL/min, UV detection at 210 and 280 nm) to yield 80 fractions (F1–F80). 
Fraction F33 was further purified using semipreparative HPLC (Zorbax C18, 9.4 × 250 mm, gradient 
H2O/CH3CN from 50% to 56% CH3CN in 35 min, flow rate 3.6 mL/min, UV detection at 210 and 
280 nm) to yield the bioactive pure compound 1 (1.0 mg). 
Chromomycin A2 (1): yellow amorphous solid; UV (MeOH) λmax 279 nm; 1H NMR spectrum 
(CDCl3): δ 1.22 (d, J = 7.0 Hz), 1.23 (d, J = 7.0 Hz), 1.25 (d, J = 6.5 Hz), 1.30 (t, J = 5.7 Hz), 1.36 (s), 
1.37 (d, J = 4.4 Hz), 1.39 (t, J = 6.7 Hz), 1.72 (m), 1.76 (m), 2.06 (m), 2.18 (s, CH3), 2.19 (s, CH3), 
2.30 (dd, J = 13.3 and 5.4 Hz), 2.49 (dd, J = 12.0 and 5.4 Hz), 2.62 (m), 2.65 (m), 2.70 (m), 3.13 (m), 
3.23 (d, J = 2.6 Hz), 3.32 (m), 3.39 (m), 3.52 (s, OCH3), 3.61 (s, OCH3), 3.82 (q, J = 6.5 Hz), 3.89 (q,  
J = 6.5 Hz), 4.01 (m), 4.23 (s), 4.37 (q, J = 6.5 Hz), 4.61 (d, J = 9.4 Hz), 4.72 (d, J = 2.7 Hz), 5.03 (sl), 
5.10 (d, J = 9.9 Hz), 5.13 (s), 5.18 (sl), 5.23 (d, J = 9.7 Hz), 6.65 (s), 6.76 (s), 9.82 (s), 15.7 (s); 
HRESIMS m/z 1211.5476 [M + H]+ (calcd. for C59H87O26, 1211.5480).  
3.4. Cytotoxicity Assay 
Cytotoxic activity of 1 was evaluated against six different human tumor cell lines, HCT-116 (colon 
adenocarcinoma), HL-60 (leukemia), MALME-3M (metastatic melanoma), OVCAR-8 (ovarian 
carcinoma), PC-3M (metastatic prostate carcinoma) and SF-295 (glioblastoma), and a human  
non-tumor cell line MRC-5 (fetal lung fibroblast). MALME-3M cells were maintained in IMDM 
medium supplemented with 20% fetal bovine serum (v/v), 100 U/mL penicillin and 100 µg/mL 
streptomycin, and the other cell lines were maintained in RPMI 1640 medium supplemented with 10% 
fetal bovine serum (v/v), 2 mM glutamine, 100 U/mL penicillin and 100 µg/mL streptomycin. All cells 
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were kept at 37 °C under a 5% CO2 atmosphere. Cell cultures were regularly split to keep them in a 
logarithmic growth phase. IC50 values were determined using the MTT assay [48]. Cells were plated 
into 96-well plates (3 × 105 cells/mL for suspended leukemia cells and 5 × 104 cells/mL for adherent 
solid tumor cells). Adherent cells were plated 24 h prior to addition of C-A2 and incubated for 24, 48 
or 72 h. Negative controls received DMSO, whereas positive controls received doxorubicin. Three 
hours before the end of the incubation periods, 150 µL of a stock solution (0.5 mg/mL) of MTT  
(3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) was added to each well, and, 3 h 
later, removed. Absorbance was measured using a multiplate reader (Fisher Scientific, model 
Multiskan FC, Hampton, VI, USA). The effect was quantified as the percentage of the control 
absorbance at 595 nm and IC50 values, along with 95% confidence intervals, were calculated by  
non-linear regression using GraphPad Prism 4.0 (Intuitive Software for Science, La Jolla, CA, USA). 
3.5. Cell Viability Analyses 
MALME-3M cells were seeded in a 24-well plate (5 × 104 cells/mL) and treated with 1 at 10 or 
30 nM for 48 h along with 0.4% DMSO (v/v) or 100 nM doxorubicin, as negative and positive 
controls, respectively. Cells were harvested with trypsin-EDTA 0.05% (Gibco), centrifuged and 
resuspended in a 5 µg/mL propidium iodide (PI) solution (Sigma Aldrich). After 5 min incubation in 
the dark, five thousand events were acquired using the Accuri C6 flow cytometer (BD Biosciences, 
Franklin Lakes, NJ, USA), on a gated region to exclude debris and doublets from the analysis 
(supplementary Figure S5). The experiments were repeated at least three times. The differences 
between negative control and experimental groups were determined by analysis of variance (ANOVA) 
followed by Dunnett’s test on GraphPad Software 4.0 (Intuitive Software for Science, La Jolla, CA, 
USA). The minimal significance level was set at p < 0.05. 
3.6. Cell Cycle and DNA Fragmentation Analyses 
MALME-3M cells seeded in a 24-well plate (5 × 104 cells/mL), were treated with 1 at 10 or 30 nM, 
or controls. After 48 h exposure period, cells were collected from the plate with trypsin-EDTA 0.05% 
(Gibco, Saint Louis, MI, USA), centrifuged and resuspended in a solution containing 5 µg/mL PI, 
0.1% citrate and 0.1% Triton X-100. After 30 min incubation in the dark, five thousand events were 
acquired on the Accuri C6 flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA) set with gated 
regions to exclude debris and doublets from the analysis (Supplementary Figure S6). Cell cycle 
histograms were acquired with the FL3 channel set in linear scale. Cell cycle profile was then analyzed 
with the ModFit LT 3.3 software (Verity Software House, Topsham, ME, USA) to determine the 
respective percentages of cells in G1/G0, S and G2/M phases. Moreover, sub-G1/G0 cells, which 
relates to those undergoing DNA fragmentation and loss, were also accounted in the cell cycle profile 
analysis. The experiments were repeated at least three times. Differences between negative control and 
experimental groups were determined by analysis of variance (ANOVA) followed by Dunnett’s test 
using GraphPad Software 4.0 (Intuitive Software for Science, La Jolla, CA, USA). The minimal 
significance level was set at p < 0.05. 
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3.7. Morphological Analysis 
MALME-3M cells were seeded (5 × 104 cells/mL) in 24-well plates pre-planted with sterile 
coverslips and treated with 1 at 10 or 30 nM 1, or controls. After 48 h exposure, cells were fixed and 
stained using a kit for fast staining of hematologic cells (Quick Panoptic Kit, Laboclin, Paraná). 
Untreated or treated cells were examined for morphological changes under light microscopy 
(Olympus, model BX-41, Miami, FL, USA). 
3.8. Detection and Quantification of Acidic Vesicular Organelles (AVOs) 
Detection of AVOs was conducted by treating MALME-3M cells (3 × 104 cells/mL) in a 35 mm 
glass-bottom culture dish (MatTek Corporation, Ashland, OR, USA) with 10 and 30 nM 1, or controls, for 
48 h. Next, acridine orange (AO) was added at a final concentration of 1 µg/mL for a period of 15 min 
in the dark at 37 °C [46] and images were obtained on an inverted confocal microscope with a  
Plan-APOCHROMAT® 63×/1.40 objective (LSM 710, Zeiss, Oberkochen, Germany). 
To quantify the development of AVOs, cells were seeded in a 24-well plate (5 × 104 cells/mL), and 
treated as described above. After 48 h treatment, cells were harvested with trypsin-EDTA 0.05% 
(Gibco, Saint Louis, MI, USA), centrifuged and resuspended in a 1 µg/mL AO solution. After 15 min 
incubation in the dark at 37 °C, cells were washed with Dulbeccos’s phosphate buffered saline (PBS). 
Then five thousands events were acquired in a gated region set in a FSC vs. SSC dot plot graph to 
exclude debris using Accuri C6 flow cytometer and Accuri C6 software (BD Biosciences, Franklin 
Lakes, NJ, USA). AVOs were detected in a gate set in high fluorescence level of FL3 channel. The 
experiments were repeated at least three times. The differences between negative control AVOs and 
experimental groups were determined by analysis of variance (ANOVA) followed by Dunnett’s test 
using GraphPad Software 4.0 (Intuitive Software for Science, La Jolla, CA, USA). The minimal 
significance level was set at p < 0.05. 
3.9. Western Blot 
MALME-3M cell were seeded in a 6-well plate (5 × 104 cells/mL) and treated with 1 at 10 or 
30 nM, or controls, for 48 h. Suspended cells were collected, centrifuged, washed with PBS, 
resuspended with 150 µL of radioimmunoprecipitation assay (RIPA) buffer (Sigma Aldrich，Saint 
Louis, MI, USA) and returned to the plate for collection of adhered cells, which were previously 
washed with PBS. After 20 min in an ice-cold recipient, cells were transferred to a 1.5 mL tube, lysed 
by sonication for 10s and centrifuged at 13,700× g. The supernatant was collected and the protein 
concentration therein was determined by a modified Lowry analysis (BioRad Laboratories, Hercules, 
CA, USA) in comparison with bovine serum albumin (BSA) standards and analyzed on GraphPad 
Prism 4.0. Samples containing 10 µg of total protein extract from each treatment were diluted with 2× 
Laemmlli buffer (Bio-Rad, Hercules, CA, USA) and loaded onto a 5%–12.5% gradient SDS-PAGE gel 
placed in Tris-Glycine-SDS buffer (25 mM Tris, 192 mM glycine, 0.1% SDS (w/v), pH 8.3). After 
running the electrophoresis for nearly 2 h 40 min at 120 V and 40 mA, proteins were then transferred 
from the gel onto a Hybond-P PVDF membrane (GE Healthcare, Little Chalfont, UK) in  
Tris-glycine-MeOH transfer buffer (25 mM Tris, 192 mM glycine, 20% MeOH (v/v); BioRad 
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Laboratories, Hercules, CA, USA) at 300 mA and 100 V for 1 h 20 min. The membrane was blocked 
for 30 min with 5% non-fat dried milk (w/v) in tris-buffered saline (TBS) and then washed 3 times in 
TBS-T (137 mM NaCl, 20 mM Tris, 0.1% Tween 20 (w/v), pH 7.6). Next, the membrane was 
incubated overnight, at 4 °C, with the ascribed primary antibody diluted at 1:1000 in BSA 5% in TBS 
(137 mM NaCl, 20 mM Tris-HCl, pH 7.6). The membrane was then washed 3 times with TBS-T, 
incubated for 1 h in room temperature with the appropriate alkaline phosphatase linked secondary 
antibody diluted to 1:2000 in 5% non-fat dried milk (w/v) in TBS. The membrane was washed with 
TBS-T and developed using a 1-step NBT/BCIP solution (Sigma-Aldrich, Saint Louis, MI, USA). The 
following primary antibodies were used, cyclin A2, cyclin D1, cyclin D3, LC3-A, LC3-B, beclin-1, 
caspase-3, caspase-3 cleaved, PARP, cleaved PARP and β-actin, as a loading control. Anti-rabbit IgG 
and anti-mouse IgG were used as secondary antibodies. All antibodies were obtained from Cell 
Signaling Technology, Inc. (Beverly, MA, USA). 
4. Conclusions 
The present work described the autophagy-inducing effects of chromomycin A2 in a metastatic 
melanoma cell line. Biochemical evidences collected experimentally to support this statement include 
increased expression of beclin-1 and lipidation of the autophagosomal markers LC3-A and LC3-B, 
while morphological evidences are depicted by the appearance of acidic vacuoles organelles, as well as 
numerous cellular rounded cytoplasm-containing vesicles surrounding the nucleus, resembling 
autophagosomes. Although chromomycins are well known for their anticancer activity, this is the first 
report of autophagy induction by this class of compounds.  
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